Lupin gets USFDA nod to market generic drug

Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic product, used in the treatment of a lung disease, in the American market.

Pirfenidone is used for the treatment of idiopathic pulmonary fibrosis. Pic: Reuters

Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic product, used in the treatment of a lung disease, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market Pirfenidone tablets in strengths of 267 mg and 801 mg, the Mumbai-based drug maker said in a statement.

The company's product is the generic equivalent of La Roche Inc's Esbriet tablets, it added.

Also Read: Anil Agarwal says mulling separate listing of different businesses